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ABSTRACT Chronic obstructive pulmonary disease (COPD) is currently the third most common cause
of global mortality. Acute exacerbations of COPD frequently necessitate hospital admission to enable more
intensive therapy, incurring significant healthcare costs. COPD exacerbations are also associated with
accelerated lung function decline and increased risk of mortality. Until recently, bacterial pathogens were
believed to be responsible for the majority of disease exacerbations. However, with the advent of culture-
independent molecular diagnostic techniques it is now estimated that viruses are detected during half of all
COPD exacerbations and are associated with poorer clinical outcomes. Human rhinovirus, respiratory
syncytial virus and influenza are the most commonly detected viruses during exacerbation. The role of
persistent viral infection (adenovirus) has also been postulated as a potential pathogenic mechanism in
COPD. Viral pathogens may play an important role in driving COPD progression by acting as triggers for
exacerbation and subsequent lung function decline whilst the role of chronic viral infection remains a
plausible hypothesis that requires further evaluation. There are currently no effective antiviral strategies for
patients with COPD. Herein, we focus on the current understanding of the cellular and molecular
mechanisms of respiratory viral infection in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide.
Recent estimates indicate that COPD affects one in 10 people globally and is now the third leading cause
of death in the USA [1]. There are currently at least 15 million COPD sufferers in the USA [1, 2] and in
2015 the disease was estimated to affect approximately 174 million people globally [3, 4]. Despite the
rising prevalence of COPD it is a disease that has received insufficient funding [5]. The clinical course of
the disease is associated with a downward spiral of progressive breathlessness punctuated by episodes of
acute exacerbation leading to heightened symptom severity and increased risk of mortality [6]. Acute
exacerbations of COPD (AECOPD) frequently necessitate hospital admission and are responsible for
enormous healthcare costs. In 2005 the European Union (EU) reported that the direct healthcare cost
attributable to COPD was €38.6 billion [7] whilst in the USA $50 billion are spent on COPD annually [1].
AECOPD is also associated with accelerated lung function decline and thus implicated in disease
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progression [6, 8–10]. The growing pressure facing our health services is an important driver to improve
the outcome for this disease; however, there are currently no treatments that can meaningfully alter the
course of deteriorating lung function or the time to death in COPD. Future research urgently needs to
focus on the development of novel therapies. Growing evidence indicates that the majority of disease
exacerbations are associated with respiratory viruses and bacteria [11, 12]. Improved understanding of the
underlying mechanisms implicated in virus-associated disease exacerbations may help to facilitate the
development of potential novel therapies that might serve to reduce exacerbations and hinder disease
progression in COPD.
Pathogenesis of airway inflammation in COPD
COPD is characterised by an enhanced inflammatory response of the airway epithelium to inhaled noxious
gases and particles, primarily cigarette smoke [13]. Combustion products from biomass fuel, occupational
dust and particulate matter from air pollution are important risk factors in non-smokers [3, 13, 14]. There
is extensive evidence demonstrating that both protease/anti-protease imbalance and oxidative stress are
viable pro-inflammatory mechanisms that contribute to pathogenesis in COPD [15–28]. Only a proportion
of smokers develop COPD suggesting that host factors may also be implicated in disease pathogenesis [29,
30]. The neutrophil is a key effector cell that accumulates within the airway mucosa in COPD [31, 32].
Sustained activation of the innate immune response leads to increased episodic neutrophilic inflammation
[32, 33]. Dysregulation of adaptive immune mechanisms are also implicated in the chronic inflammation
and irreversible “airway remodelling” seen in COPD [13, 34, 35]. T-lymphocytes are believed to play an
important role in regulating inflammation in COPD [34]. Resected small airway specimens from subjects
with COPD demonstrate an increased number of CD8+ T-lymphocytes and their organisation into
lymphoid follicles [13]. The degree of activated immune cell accumulation within the airway mucosa has
been shown to correlate strongly with severity of airflow obstruction [13]. CD8+ T-lymphocytes provide
adaptive immune defence against viruses; however, they also pose the potential to cause tissue injury
through a variety of mechanisms including direct cytotoxic effects, pro-inflammatory signalling and
recruitment of other immune cells [34, 36, 37]. Physiologically, CD8+ T-cells normally undergo
Fas-induced apoptosis following viral eradication. The finding of abundant CD8+ T-cells and the
organisation of B-cells into lymphoid follicles within the airway epithelium in COPD has been suggested
to represent an increased “immune surveillance” of the airway mucosa [13]. These findings have fuelled
the hypothesis that an additional aetiological factor other than exposure to inhaled noxious agents may be
necessary in order to develop COPD. A chronic viral infection could potentially account for this finding.
Viral detection during acute exacerbations of COPD
COPD exacerbations arise in the setting of complex interactions between the host, airway pathogens and
environmental pollution [38, 39]. AECOPD leads to lung function decline across the severity spectrum of
COPD [6, 8] and patients who suffer from frequent or severe exacerbations experience a more accelerated
decline in lung function [6, 40]. Until recently bacteria were believed to be responsible for the majority of
exacerbations; however, with the advent of PCR testing the true prevalence of respiratory viruses has been
realised [11, 39, 41, 42]. Early studies using serological and viral culture techniques identified viruses in
∼10–30% of AECOPD [39, 43]. Following the implementation of PCR it is now estimated that viruses are
associated with half of all exacerbations [39, 41, 42, 44]. ROHDE et al. [45] detected respiratory viruses in
56% of exacerbations using PCR. Respiratory viral infection is associated with poorer clinical outcomes
including increased symptom severity and longer duration of hospital stay [41, 44, 46]. A recent systematic
review of 19 studies using sputum PCR during AECOPD (n=1972) reported that the most frequently
detected viral species are human rhinovirus (HRV) (16.39%), respiratory syncytial virus (RSV) (9.9%) and
influenza (7.83%) [11]. Adenovirus (2.07%), coronavirus (4.08%) and human metapneumovirus (2.78%)
are detected less frequently [11]. The predominance of HRV, RSV and influenza reflect increased
likelihood of infection with these viruses because of co-circulation of multiple genotypes (HRV) and the
yearly community wide epidemics of RSV and influenza. This epidemiological data implicates viruses in a
significant proportion of COPD exacerbations, however, these findings do not demonstrate causality.
Respiratory virus detection in stable COPD has also been reported. MCMANUS et al. [41] detected viruses
in 12% whilst ROHDE et al. [45] detected viruses in 19% of stable COPD subjects. PCR may detect minute
quantities of viral DNA or RNA and does not confirm the presence of live virus [39]. Bacterial and viral
co-infection has also been described in the context of AECOPD leading some to question whether viral
pathogens simply contribute to secondary bacterial infection [39, 47]. Based on these findings the role of
viruses during COPD exacerbations remains controversial.
Mechanisms of virus-induced COPD exacerbations
The mechanisms of virus-induced COPD exacerbation remain poorly elucidated and clinical data is
currently lacking. Respiratory viruses preferentially target airway epithelial cells leading to epithelial cell
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sloughing, microvascular dilatation, oedema and immune cell infiltration [48]. There is increased
susceptibility to bacterial infection and impaired mucociliary clearance [48, 49]. HRV is the most
commonly detected virus during disease exacerbations and the virus that has been studied to the greatest
extent in the context of AECOPD. In pursuit of demonstrating causality MALLIA and co-workers [50, 51]
have conducted human experimental models measuring clinical symptoms, lung function and
inflammatory response biomarkers in subjects with COPD following nasally administered rhinovirus
inoculum (RV16). Subjects with COPD develop peak cold symptoms at day 10–11 post-inoculation and
subsequent exacerbation following 10 to 1000 lower doses of RV16 than those used in subjects with
asthma during previous studies [50]. Subjects with COPD experienced forced expiratory volume in 1 s
(FEV1) reduction and increased nasal lavage interleukin (IL)-8 following HRV infection [50]. RV16 viral
inoculum has been shown to result in significant increases in sputum neutrophilia and there is correlation
between sputum neutrophil elastase, symptom severity and airflow obstruction in subjects with COPD
[51]. These findings suggest HRV is a viable inducer of COPD exacerbation [51]. More recently, FOOTITT
et al. [52] demonstrated increased indices of oxidative and nitrosative stress and impaired macrophage
activity (histone deacetylase, HDAC2) following HRV infection in COPD. The toll-like receptor (TLR)-3
pathway signalling may be implicated in RSV-induced exacerbation [53, 54]. Several studies suggest that
viral infection is associated with more frequent and more severe exacerbations [42, 44, 55]. One
exacerbation study reported that sputum eosinophilia occurred in the context of viral exacerbation but not
bacterial infection [47].
Mechanisms of increased susceptibility to viral infection in COPD
The finding of increased viral load in COPD relative to control subjects following HRV infection suggests
that innate antiviral immunity may be deficient [51, 52]. The innate antiviral response following HRV
infection relies on interferon signalling, however, this has been shown to be impaired in COPD [51].
Furthermore, the simultaneous insult of cigarette smoke exposure and HRV infection may contribute to
increased host susceptibility through inhibiting expression of “interferon simulated genes” and may affect
interferon production [56]. A further mechanism of susceptibility to HRV in COPD may be related to
increased airway expression of intracellular adhesion molecule (ICAM)-1 in smokers with chronic airflow
limitation [57]. MCKENDRY et al. [58] recently used an ex vivo infection model to demonstrate that CD8+
cells from subjects with COPD have a defective response to H3N2 influenza virus in vitro. Programmed
cell death protein-1 (PD-1) (also known as CD279) exerts numerous immunosuppressive actions on CD8+
T-cells and appears to be central to this process. In subjects with COPD, PD-1 expression is upregulated
in lung CD8+ T-cells compared to unaffected controls following influenza infection [58]. This study also
demonstrated reduced T-cell cytotoxicity [58]. These findings indicate that virus-specific mechanisms of
susceptibility exist in COPD. Continued cigarette smoke exposure adds insult to injury through
impairment of innate immunity. Cigarette smoking is the primary risk factor for COPD and has been
shown to impair viral recognition and innate immune responses [59]. Cigarette smoke extract (CSE)
pre-treatment of primary bronchial epithelial cells (pBECs) results in a relative immunosuppressive effect
with reduced expression of IL-6 and IL-8 in subjects with COPD compared to controls and unaffected
smokers [60]. CSE has also been shown to alter host anti-viral immune signalling via reduction in
viral-mediated interferon (IFN)-β and Retinoic Acid Inducible Gene (RIG)-1 mRNA expression [61].
Dysregulation of adaptive immunity may be an important disease mechanism in COPD and may render
patients with COPD more susceptible to acute viral infection. CSE also modulates airway epithelial cell
cytokine release in the setting of rhinovirus infection and has been shown to increase the release of
CXCL8 [62]. In addition, CSE demonstrates potent inhibition of rhinovirus-induced release of CXCL10
[63]. CXCL10 knockout mice demonstrate reduced ability to control viral infection and impaired T-cell
recruitment and activation. Those engaged in the ongoing debate regarding the role for inhaled
corticosteroids (ICS) in COPD should consider recent data published by SINGANAYAGAM et al. [64] showing
that fluticasone propionate leads to impairment of both innate and adaptive antiviral immunity and may
also contribute to increased mucous production, increased bacterial load and impaired antimicrobial
peptide secretion. Furthermore, the finding of herpes simplex virus (HSV)-1 in COPD should alert
prescribers. HSV-1 is more commonly detected in those taking higher ICS doses and associated with
increased risk of mortality [65].
Chronic viral infection in COPD
In 2004, HOGG et al. [13] postulated that the formation of lymphoid follicles and adaptive immune cell
infiltration within the airway epithelium in COPD could potentially be explained by “microbial
colonisation”. A chronic viral infection could account for this finding. Previous attention has focused on
persistence of RSV and latent adenovirus infection [44, 66, 67]. However, several epidemiological studies
have failed to demonstrate persistence of these pathogens in stable COPD [41, 68, 69]. The adenovirus
E1A protein has been shown to be associated with emphysema and appears to upregulate
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pro-inflammatory signalling [67, 70, 71]. HSV-1 and Epstein–Barr virus (EBV) may be underestimated in
COPD. Human herpes virus infections demonstrate persistence with the ability to cause recurrent
infection. In one study our group identified HSV-1 in the sputum of 19% of a cohort of patients admitted
to hospital (21 out of 112) [65]. In this study HSV-1 was associated with higher doses of inhaled steroids,
worse lung function and an increased risk of mortality [65]. In another study the detection of EBV DNA
via PCR was significantly increased in the sputum of subjects with COPD but not unaffected smokers
[72]. Interestingly, EBV copy numbers were similarly elevated in stable COPD [72]. POLOSUKHIN et al. [73]
performed immunohistochemistry using lung biopsy specimens demonstrating that small airway
inflammation and remodelling is associated with the presence of EBV. Further clinical and mechanistic
data is necessary to evaluate the significance of human herpes virus infections in the pathogenesis of
COPD.
Rhinovirus infection and COPD
During COPD exacerbation HRV is the most frequently detected respiratory virus [11]. Viral infections
may be underestimated because colds, mostly associated with acute viral infection, predict AECOPD even
in the absence of detectable virus [74]. HRV is a positive unenveloped single stranded RNA virus that
belongs to the Picornaviridae family [75]. Over 100 different HRV serotypes exist [76]. Rhinovirus is
perceived as a cause of minor illness; however, it is frequently detected in COPD patients with hypoxic
respiratory failure in the absence of other pathogens [76, 77]. HRV infection during childhood is known
to predispose to the later development of asthma [76]. There is currently no treatment or vaccine for HRV
infection. Human experimental models by MALLIA and co-workers [50, 51] demonstrate that HRV is
capable of inducing AECOPD. Viral load has been shown to peak at day 5 post inoculation and prolonged
HRV shedding has been shown to occur [55, 78]. Re-infection with multiple HRV sub-types can occur
and this is more common in subjects with COPD [78]. Unlike other respiratory viruses, such as influenza,
HRV infection does not lead to significant airway epithelial damage. HRV infection in subjects with
COPD elicits pro-inflammatory cytokines (figure 1) including IL-6, IL-8, tumour necrosis factor (TNF)-α,
growth regulated oncogene (GRO)-α, IFN-γ-induced protein 10, RANTES, eotaxin-1, ICAM-1 and
neutrophil elastase via activation of nuclear factor (NF)-кB [79–82]. HRV also activates epidermal growth
factor receptor to release mucin and IL-8 (figure 2) [83]. HRV airway epithelial attachment is mediated via
ICAM-1 (CD54) in over 60% of serotypes [84]. ICAM-1 is also involved in leukocyte recruitment and
activation. ICAM-1 has been shown to be markedly elevated in COPD [57] potentially promoting
enhanced HRV binding and entry into the airway epithelial cells [39, 42, 57, 76]. Thus, ICAM-1 has been
seen to represent a potential therapeutic target and ICAM-1 inhibition in transgenic mice reduces
inflammation, cytokine production and virus load [76]. However, ICAM-1 inhibition also has the potential
to impair innate immune capabilities and increase the risk of bacterial infection.
Rhinovirus-induced alterations in lower airway microbiome
A study by MALLIA et al. [85] reported that following experimental HRV infection in COPD, 60% of
subjects demonstrated positive bacterial growth in sputum cultures. Peak sputum viral load precedes peak
bacterial load by up to 10 days [85]. The microbiome of subjects with COPD has been shown to differ at
baseline from those of normal individuals with lower numbers of proteobacterial species present in COPD
[82]. Interestingly, HRV infection induces alterations to the lower airway microbiome in COPD that persist
for up to 42 days with a tendency toward pathogenic outgrowths of Haemophilus influenzae [82]. This
does not occur in unaffected smokers or controls and these subjects demonstrate temporal stability of the
microbiome [82]. There is increased bacterial binding and transmigration across well-differentiated airway
epithelial cells (16HBE14o) following HRV infection [75]. Viral replication appears to facilitate this
process and may be necessary for bacterial transmigration to occur in specific bacterial species such as
non-typeable H. influenzae (NTHi) [75]. Pseudomonas aeruginosa is capable of epithelial transmigration
in the absence of viral replication, however, higher rates of cell damage occur in the presence of HRV [75].
These findings suggest that HRV replication supports bacterial transmigration and is relevant to numerous
bacterial species that are prevalent in AECOPD [77]. HRV also impairs the airway epithelial barrier by
dissociating zona occludens-1 from the tight junction complex [75].
Rhinovirus-induced impairment of innate immune capabilities in COPD
Rhinovirus may lead to impairment of innate immune capabilities increasing susceptibility to bacterial
infection in subjects with COPD via reduction in sputum antimicrobial peptides including elafin and
secretory leukocyte protease inhibitor (SLPI) [85]. Concurrent infection with rhinovirus and NTHi induces
synergistic CCL20 production by bronchial epithelial cells that exceeds isolated bacterial or virus infection
alone [86]. Airway epithelial cells taken from subjects with COPD demonstrate a pro-inflammatory
phenotype at baseline and greater susceptibility to rhinovirus infection [80]. Subsequent increase in the
viral load may enhance type 3 IFN responses [80]. These cells also demonstrate increased susceptibility to
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apoptosis following HRV infection. SINGH et al. [87] reported that HRV-encoded proteinase 2A induces
both T-helper (Th)1 and Th2 responses from CD4+ T-cells and monocyte-derived dendritic cell activation
in rhinovirus-initiated acute COPD exacerbation. The subsequent Th2 response results in elevated airway
hyperactivity and contributes to more severe dyspnoea and accelerated lung function deterioration [42, 49].
Respiratory syncytial virus in COPD
RSV, a negative single stranded RNA, enveloped virus, is the most common cause of bronchiolitis and is
the single most important cause of respiratory illness in the paediatric population. Symptom severity
during adult RSV infection is typically milder in adults. However, FALSEY et al. [88] estimated that the
impact of RSV within both elderly and “high-risk” groups was similar to that of non-pandemic influenza
A. One retrospective multicentre study reported a 12.6% 60-day mortality during RSV-associated COPD
exacerbations [89]. RSV contributes to airway inflammation via cytokine release and neutrophil and CD8+
recruitment and has been shown to activate epidermal growth factor receptor leading to suppression of
CXCL10 production resulting in impaired viral clearance via reduced NK cell and T-lymphocyte
recruitment [90, 91]. Mechanistic data demonstrates that RSV infection promotes P. aeruginosa-mediated
biofilm formation [92]. In vitro data show that A549 cells show increased expression of TLR3 following
RSV infection [53]. This leads to increased NF-kB activity and IL-8 release [54]. Together these
mechanisms sensitise the airway epithelium to ds-DNA exposure. Increased TLR3 expression in COPD is
associated with declining lung function and may be a risk factor for RSV-induced AECOPD [53]. It
remains unclear which COPD patients are at highest risk from RSV infection. One study (n=379) using
logistic regression analysis demonstrated that the presence of “congestive cardiac failure” and/or “exposure
to children” were independent risk factors for the development of severe COPD exacerbations [93].
Interestingly, a number of studies have shown high rates of RSV detection during stable COPD [44, 91].
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FIGURE 1 Protease/anti-protease imbalance and oxidative stress are viable pro-inflammatory mechanisms that contribute to the pathogenesis of
chronic obstructive pulmonary disease (COPD). Cigarette smoke and inhaled noxious agents activate epithelial cells and macrophages to release
several chemotactic factors (including interferon-γ-induced protein 10 (IP10), monokine-induced by interferon-γ (MIG), I-TAC, interleukin (IL)-6,
IL-8 and leukotriene B4 (LTB4)), which attract and activate key inflammatory cells that accumulate within the airway mucosa in COPD. Sustained
activation of innate and adaptive immune responses leads to airway influx of neutrophils and CD8 cytotoxic T-cells (TC1 cells)/CD4 T-helper 1
(Th1) cells. In a sub-group of COPD patients, increased Th2 signalling may be present and numerous therapies targeted at Th2 cytokines have
been studied. Mepolizumab (IL-5) has shown minor reduction in acute exacerbations of COPD whilst benralizumab (IL5Ra) and navarixin (CXCR2)
have shown a modest effect on forced expiratory volume in 1 s. COPD inflammatory mediators sustain the inflammatory process in COPD leading
to elastin degradation and emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cells and macrophages also release
transforming growth factor (TGF)-β, which stimulates fibroblast proliferation resulting in small airway fibrosis and remodelling. The finding of
CD8+ T- and B-cells organised into follicles within the airway epithelium in COPD may represent an increased “immune surveillance” of the
airway fuelling the hypothesis that an additional aetiological factor, other than exposure to inhaled noxious agents, is necessary in order to
develop COPD. Chronic viral infection might serve as an additional host aetiological factor (the “missing link”) in the development of COPD, whilst
increased susceptibility to acute viral-induced exacerbations leads to incremental disease progression. CTGF: connective tissue growth factor;
CPE: cytopathogenic effect; TNF: tumour necrosis factor.
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SEEMUNGAL et al. [44] reported detection of RSV in 23.5% of stable COPD patients. These findings led the
authors to postulate a potential “chronic low-grade infection with RSV” [44]. There was also a tendency
towards higher nasal lavage IL-6 and serum carbon dioxide, however, these findings did not reach
statistical significance. Subsequent studies have not demonstrated significant levels of RSV detection in
stable COPD [11, 41]. FALSEY et al. [68] investigated RSV persistence in a study of 112 COPD subjects
experiencing AECOPD and detected RSV in none out of 685 routine nasal samples and three out of 315
sputum samples. More recently, MCMANUS et al. [41] reported RSV was not detected using real-time PCR
Cytokines
TNF-α
IL-6
GM-CSF
GRO-α
Th1
B-cell
T-cell Neutrophil
Macrophage
Eosinophil
CD8+
TH2
(   ) Inflammatory mediators and apoptosis via virus-induced NF-κB activation;
(   ) IFN and ISG production; (   ) MMP-9, airway remodelling
Mucus plugging
   Epithelial cell sloughing, oedema,    mucociliary clearance
Impaired
tight junction
Chemokines
IL-8
MIG
IP-10
I-TAC
ENA-78
Eotaxin-1
RANTES
LTB4
ICAM-1
Neutrophil elastase
MMP
TGF-β
VEGF/EGF
(   ) Immune cell infiltration, Th1/Th2 skew, (   ) apoptosis, dysregulation of adaptive immunity
Viral replication
Bacterial load
Chemotaxis
FIGURE 2 Mechanisms of virus-induced airway inflammation in chronic obstructive pulmonary disease
(COPD). COPD exacerbations are associated with increased expression of cytokines and chemokines,
including tumour necrosis factor (TNF)-α, interleukin (IL)-6, interferon (IFN)-γ-induced protein 10 (IP10),
leukotriene B4 (LTB4), monokine-induced by IFN-γ (MIG), IFN-inducible T-cell-α chemoattractant and
RANTES, growth regulated gene α (GRO-α) and epithelial-neutrophil activating peptide (ENA-78). These
cytokines and chemokines attract various inflammatory cells such as neutrophils, T-cells, macrophages and
dendritic cells. Vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) promote the
release of matrix proteins from fibroblasts/myofibroblasts, which enhance the production of matrix
metalloproteinases (i.e. MMP-9) from airway epithelial cells leading to airway remodelling. Respiratory
viruses preferentially target airway epithelial cells leading to epithelial cell sloughing, Goblet cell hyperplasia
(mucus plug), microvascular dilatation, oedema and immune cell infiltration. Consequently, there is increased
impaired mucociliary clearance and increased susceptibility to bacterial infection. Cigarette smoke
contributes to impaired host innate antiviral immunity through the reduction of IFNs and IFN-stimulated gene
production, and induces inflammatory mediators in the airway and increased epithelial cell apoptosis via the
activation of nuclear factor (NF)-κB. In addition, dysregulated adaptive immunity may also be an important
disease mechanism that may render patients with COPD more susceptible to acute viral infection. GM-CSF:
granulocyte-macrophage colony stimulating factor; ICAM: intracellular adhesion molecule; TGF: transforming
growth factor; I-TAC: interferon-inducible T-cell alpha chemoattractant; ISG: interferon stimulated genes;
Th1: T-helper cell type 1.
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in any stable phase COPD subjects. GIANNAKAKI et al. [94] reported that RSV was not detected in the
bronchoalveolar lavage or lung biopsy specimens of subjects with COPD (n=31). These findings do not
support the hypothesis that chronic RSV infection is implicated in the pathogenesis of COPD, however,
RSV may be underestimated as a cause of morbidity and mortality in “at risk” elderly patients and also
appears to be a less common trigger of COPD exacerbation.
Influenza infection and COPD
There is a paucity of specific clinical studies relating to influenza infection in the setting of COPD. One
study reported that COPD was a statistically significant risk factor for hospital admission during influenza
infection whilst asthma was not [95]. Influenza is the second most common respiratory virus detected
during AECOPD [11]. ROHDE et al. [45] reported detection of influenza in 25% of exacerbations whilst
TAN et al. [96] found influenza in 36%, however this was a small study and patients had not received the
influenza vaccination. There is increased lethality following influenza infection in subjects with COPD
compared to normal individuals [97]. Numerous randomised control trials (RCT) have shown that
influenza vaccination reduces COPD exacerbations [98–100] whilst population-based and observational
studies demonstrate that vaccination reduces the incidence of pneumonia, critical care admissions and
mortality [101, 102]. Nevertheless, vaccination coverage rates are below target levels in both the USA and
EU [103]. One possible reason for this suboptimal vaccine coverage in COPD sufferers is a perceived risk
of exacerbation and impaired immune response with subsequent infection has been reported [99, 104]. In
rare circumstances influenza vaccination has been reported to be associated with eosinophilic pneumonia
and respiratory failure [105]. Numerous studies have shown no evidence of increased exacerbation risk
[103, 106, 107] and a systematic review conducted in 2017 reported that influenza vaccination confers a
“positive benefit–risk ratio” in the COPD population and that existing data supports annual vaccination in
patients with COPD [103].
Secondary bacterial pneumonia may occur as a complication of influenza infection and is the predominant
cause of morbidity and mortality during pandemics [108–110]. CHERTOW et al. [109] reported up to 34% of
intensive care admissions during the 2009 influenza pandemic were complicated by bacterial co-infection.
Viral–bacterial co-infection with Streptococcus pneumonia following influenza is an established phenomenon
[108, 109, 111]. Bacterial co-infection frequently occurs within 6 days and may be difficult to differentiate
from isolated viral infection clinically, however, the consequences of co-infection are more severe [112].
Influenza is capable of suppressing the immune response to S. pneumonia and also upregulates
pneumococcal adhesion molecules [108, 109, 111]. The presence of influenza neuraminidase leads to
epithelial barrier dysfunction with subsequent increase in bacterial adherence and proliferation [113].
Influenza has also been shown to induce neutrophil apoptosis and neutrophil dysfunction [114] and may
also inhibit macrophage phagocytosis [112]. Bacterial co-infection may perpetuate inflammation during
co-infection via increased protease activity and bacterial neuraminidase expression [110]. TNF-α has been
identified as a potential biomarker for influenza-bacterial co-infection with S. pneumonia [112].
Cochrane reviews published in 2004 [115] and 2006 [116] concluded that amantadine was an effective
prophylactic agent. Amantadine and rimantadine both resulted in significant gastrointestinal side-effects
[115]. Neither drug has an effect on viral shedding and there is significant resistance to both drugs in
H3N2 influenza [117]. Neuraminidase inhibitors such as oseltamivir and zanamivir are also available for
prescription in patients with influenza including those with COPD; however, no specific RCTs in COPD
patients exist and the treatment efficacy of neuraminidase inhibitors remains dubious. In a systematic
review published in 2014, JEFFERSON et al. [118] concluded, “oseltamivir reduces the proportion of
symptomatic influenza” and “in treatment studies it also modestly reduces the time to first alleviation of
symptoms”. However, it was found that oselatmivir resulted in significant gastrointestinal side-effects,
headaches, psychiatric symptoms and renal complications [118]. Based on these findings the benefit–risk
ratio must be carefully considered prior to making the decision to commence oseltamivir in cases of
influenza [118]. The RCT data appraised by JEFFERSON et al. [118] does not relate specifically to patients
with COPD and from the current evidence base it is difficult to make recommendations regarding the
management of influenza other than to recommend annual vaccination. Some studies of “high-risk”
patients including those with COPD have shown modest effects reducing respiratory symptoms and
antibiotic usage [119].
Human adenovirus
Human adenovirus is a non-enveloped, ds-DNA virus. There are over 60 reported serotypes with seven
known species (human adenovirus-A to -G) [120]. Type 4 (group E), 7 (group B) and 1, 2 and 5 (group
C) are the subtypes most frequently implicated in adult respiratory disease [69]. Human adenovirus
infection within the lower respiratory tract can result in life-threatening infection in the context of asthma
and immunosuppression [69] and is recognised as an uncommon cause of AECOPD [11, 69, 121]. Early
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PCR studies reported adenovirus detection in 0.5–1.5% of COPD exacerbations [44, 122] and this is
concurrent with more recent systematic review data [11]. However, higher rates of detection have been
described. Notably, McMANUS et al. [69] and KOKTURK et al. [121] reported adenovirus detection during
7–10% of exacerbations.
Latent adenovirus infection has been proposed as a pathogenic mechanism in COPD. Adenovirus is
capable of persisting in the airway epithelium without active viral replication and is capable of evading the
immune response via the 19-kDa protein which delays the expression of class I human leukocyte antigen
proteins [70]. The adenoviral E1A gene is capable of integration into human DNA [123]. This E1A
protein has been shown to be present in the airway epithelial cells of COPD sufferers at higher levels than
in age-matched controls with equivalent smoking history using in situ hybridisation [66]. Subjects in
whom E1A is positive have also been shown to have lower FEV1 [70]. One study using bronchial epithelial
cells reported significantly higher E1A gene detection via PCR in subjects with COPD compared to those
with chronic bronchitis [124]. Another study demonstrated up to a 40-fold increase in the number of
alveolar epithelial cells expressing the E1A gene when cases of severe emphysema were compared to
resected lung tissue from unaffected smokers [125]. Adenovirus has been shown to amplify inflammation
following cigarette smoke exposure [70]. Guinea pig lung model data has shown that latent adenovirus-5
infection leads to enhanced inflammation following cigarette smoke exposure [126]. Adenoviral E1A
protein alters host gene expression with subsequent increase of inflammatory mediators including IL-8
and ICAM-1 [127]. Transfection of pBECs with adenoviral E1A protein and subsequent stimulation with
lipopolysaccharide leads to increased ICAM-1 expression and IL-8 mRNA compared to controls [128]. In
addition, E1A transfection of pBECs increases NF-kB binding activity compared to controls [128].
ICAM-1 promoter activity has been shown to increase up to three-fold following stimulation with TNF-α
and IFN-γ [129]. In stable E1A transfectants, ICAM-1 promoter activity is 2 to 2.5 times higher than
controls [129]. These findings suggest that E1A can modulate ICAM-1 within bronchial epithelial cells
and that this modulation differs in cells of alveolar origin [129].
Interestingly, adenovirus significantly reduces IL-6 and IL-8 release following pre-exposure to common
bacterial species such as NTHi and P. aeruginosa [130]. Adenoviral proteins E1A and E1B have been
shown to dysregulate IL-6 and IL-8 in separate experiments [131, 132]. E1A plasmid transfection induces
increased expression of connective tissue growth factor (CTGF) and transforming growth factor (TGF)-β1
mRNA from pBECs compared to control cells [67]. This increase in CTGF appears to occur
independently from the pathway through which TGF-β1 induces CTGF expression. Mesenchymal cells are
the primary source of TGF-β1 within the airway. The presence of E1A also leads to expression of
mesenchymal markers, α-smooth muscle actin and vimentin, potentially suggesting the E1A gene may
lead to a shift of airway epithelial cells towards a mesenchymal phenotype [67].
Epstein–Barr virus in COPD
EBV is an enveloped, ds-DNA virus estimated to be present in 95% of the global population [133]. The
EBV genome consists of a toroid shaped DNA core surrounded by a nucleocapsid, a lipid bilayer envelope
embedded with external glycoprotein spikes, and a protein tegument between the nucleocapsid and the
envelope [134]. EBV is a gamma herpes virus that has a complex relationship with the human immune
system. The virus has a latent and a shedding phase. When latent, it resides in the B-lymphocytes for
years at very low copies (20–100 copies per million B-cells) [135]. During the lytic phase, it infects the
respiratory epithelial cells, which shed millions of viruses. EBV latent membrane protein-1 induces CD54
(ICAM-1) on epithelial cells [136]. ICAM-1 is the principal ligand for transmigration of neutrophils into
the airway by binding neutrophil CD18/CD11b [137]. ICAM-1 is also the receptor for HRV, which has
been identified as the commonest cause of AECOPD [11]. Indeed, infection with rhinovirus then further
increases ICAM-1 expression [138]. The bacterium H. Influenzae binds to ICAM-1 and is the most
common bacterial pathogen in COPD. Moreover, EBV infection is associated with increased granulocyte-
macrophage colony stimulating factor (GM-CSF) synthesis by monocytes. These monocytes are inhibited
from maturing by EBV, adding insult to injury, as the mature pulmonary macrophages are responsible for
antigen presentation, a key immune regulatory role for infection. GM-CSF activates neutrophils which
more readily migrate across the endothelium and the airway epithelium. However, EBV causes increased
apoptosis of these neutrophils. Thus, it is apparent that EBV, in its epithelial shedding phase, sets the scene
for increased activation of the epithelium, propensity for further viral infection, adherence of H. influenzae
and failure of antigen presentation of bacteria and viruses, as well as airway neutrophil recruitment and
apoptosis. Furthermore, it has adapted to avoid antiviral responses by expressing LMP-1 (immediate early
protein) and BZLF-1 which are located on the cell wall. These inhibit IFN regulatory factor-7, subverting the
synthesis of virus inhibiting IFN-α and -β [139, 140].
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All the studies to date have focused on high levels of the virus being shed in the airway; the epithelial
shedding phase or in the epithelium itself. A study of seroprevalence in military recruits found EBV is
more common in poorer socioeconomic groups and in smokers. Poorer smokers are the very group who
go on to develop COPD [141]. Furthermore, cigarette smoke promotes viral replication.
EBV has been identified in lung biopsy specimens of subjects with idiopathic pulmonary fibrosis [142]. EBV
can frequently be detected in the lower respiratory tract specimens of patients admitted to the intensive care
unit with hypoxic respiratory failure [143]. Lower respiratory tract detection of EBV does not appear to be
associated with unfavourable clinical outcomes; however, positive EBV serology in this patient group was
associated with a significant increase in mortality [143]. Interestingly, the CD3+ T-cell count was reduced
below the normal range in EBV-positive cases [143]. These findings may suggest an association between
EBV and impaired anti-viral mechanisms within the lower respiratory tract. Impaired host defence
mechanisms have been suggested to play a role in the persistent airway epithelial inflammation that occurs in
COPD. POLOSUKHIN et al. [73] found EBV in the airway epithelium of patients with COPD using in
situ hybridisation. When examined by severity of disease, 68.2% of patients with Global Initiative for
Chronic Obstructive Lung Disease stage I and II COPD compared to 84.4% of stage III and IV
patients had EBV in their airway epithelium [73]. A low secretory immunoglobulin (Ig)A was
identified and this was attributed to the cause of EBV in the airway [73]. However, IgA is an
antibacterial antibody, it is required for inoculation of EBV into lymphocytes. EBV is a lymphotropic
virus which affects the B-cells. The relationship of EBV and low IgA could potentially be causal (rather
than low IgA causing proliferation of EBV). Indeed, in X-linked aggamaglobulinaemia patients are not
infected with EBV [144]. In the search for chronic viruses in COPD, EBV has been found in the sputum
of several groups of patients, with differing degrees of disease severity [72] and EBV DNA is more
frequently detected in COPD than in unaffected smokers [72]. Furthermore, EBV is detectable both
during stable and exacerbated disease states suggesting that EBV has persistence within the airway
epithelium in COPD [72].
Conclusion
A new appreciation has emerged for the heterogeneity that exists in COPD. It is clear that historically
favoured disease mechanisms such as protease/anti-protease imbalance and oxidative stress can only partially
explain COPD pathogenesis. Accumulating evidence demonstrates that the majority of COPD exacerbations
are associated with respiratory viruses [11]. Given that exacerbations lead to FEV1 decline, drive disease
progression and increase risk of mortality this directly implicates acute respiratory virus infection in disease
pathogenesis. However, despite the huge economic burden of COPD exacerbations, the mechanisms
underlying virus-induced exacerbations remain relatively poorly elucidated and current anti-viral therapies
are limited. The majority of acute treatments are supportive and antimicrobial prescribing is often empirical
in the absence of diagnostic microbiological samples. In the age of personalised medicine a more targeted
therapeutic approach is mandated and further research should focus on developing pathogen-specific
therapy for viral induced exacerbations There is growing interest in the Th2 signalling pathway in COPD
with a degree of emphasis placed on the presence of peripheral blood eosinophilia. Recent clinical trial data
indicates that anti-Th2 cytokine therapies offer limited benefit in COPD. However, these treatments are
costly and require further evaluation [145–147]. Similarly, the current widespread use of ICS in COPD
requires urgent attention as emerging data continues to draw our attention to the potential for harm through
impairment of antiviral immunity and risk of pneumonia [64, 65]. CD8+ T-lymphocytes provide adaptive
immune defence against viral pathogens; however, they also pose the potential to perpetuate inflammation
and may promote tissue injury through direct cytotoxic effects, pro-inflammatory signalling and recruitment
of other immune cells (macrophages, neutrophils and possibly eosinophils) [34, 36, 37]. CD8+ T-cells
normally undergo Fas-induced apoptosis after a viral pathogen has been eradicated. Consequently, the
persistence of these adaptive immune cells within the airway epithelium in COPD has led many to the
hypothesis that a chronic virus may be present. In 2004 HOGG et al. [13] demonstrated a significant
correlation between spirometric COPD severity and the presence of adaptive immune cells within the airway
epithelium and their organisation into follicles, leading the authors to postulate that there may be “immune
surveillance” of the airway in COPD. However, paradoxically there appears to be increased susceptibility of
the airway epithelium to respiratory virus infection. More recent hypotheses have suggested that genetic
differences in mucosal immunity between individuals may render subjects with COPD less able to eradicate
respiratory viral infections [148]. In conclusion, acute viruses are associated with a significant proportion of
COPD exacerbations and appear to play an important role in disease progression whilst the possibility of a
chronic viral infection in COPD remains a tempting prospect that requires further exploration.
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